Since angiogenesis is essential for the growth of any solid tumor, emerging efforts are being made to develop antiangiogenic therapy. To date, however, no antiangiogenic agent has become widely available for the clinical setting. Angiotensin I-converting enzyme (ACE) inhibitors are commonly used as antihypertensive agents and it has recently been suggested that they decrease the risk of cancer. Studies have found that an ACE inhibitor, perindopril, is a potent inhibitor of experimental tumor development and angiogenesis at a clinically comparable dose. The potent angiogenic factor, vascular endothelial growth factor (VEGF), is significantly suppressed by perindopril and also inhibits VEGF-induced tumor growth. In vitro studies showed that perindopril is not cytotoxic to either tumor cells or endothelial cells. Since perindopril is already in widespread clinical use without serious side effects, it may represent a potential new strategy for anticancer therapy.
1Third Department of Internal Medicine, Nara Medical University, Shijo-cho 840, Kashihara, Nara 634-8522, Japan
2Third Department of Internal Medicine, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho Kita-gun, Kagawa 761-0793, Japan
Correspondence to H Yoshiji, Third Department of Internal Medicine, Nara Medical University, 840-Shijo-cho, Kashihara, Nara 634-8522, Japan
Tel: (+81) 744 22 3051; Fax: (+81) 744 24 7122; E-mail: firstname.lastname@example.org
Received 5 December 2001 accepted 12 December 2001